[1] Harris PN,Ferguson JK. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides[J]. Int J Antimicrob Agents, 2012,40(4):297-305. [2] Yoo JS,Byeon J, Yang J,et al. High prevalence of extended-spectrum beta-lactamases and plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae isolated from long-term care facilities in Korea [J]. Diagn Microbiol Infect Dis,2010,67(3):261-265. [3] 赵付菊,刘文健,韩海燕,等. 老年患者医院感染前五位常见革兰阴性杆菌ESBLs和AmpC β-内酰胺酶分析[J].老年医学与保健,2013,19(3):158-160. [4] 胡付品,朱德妹,汪 复,等.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329. [5] Bush K, Jacoby GA, Medeiros AA. A functional classi-fication scheme for beta-lactamases and its correlation with molecular structure[J]. Antimicrob Agents Chemother,1995,39(6):1211-1233. [6] 林奇龙,陈琼娜,方国安,等.94株产气肠杆菌的临床分布与耐药性分析[J].中华医院感染学杂志,2012,22(16):3658-3660. [7] Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy[J]. Ann Intern Med,1991,115(8):585-590. [8] Jacoby GA. AmpC beta-lactamases[J]. Clin Microbiol Rev, 2009,22(1):161-182. |